Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
Masahito Kotaka(Shimizu (Japan)), Tae Won Kim(Asan Medical Center), Hiroyuki Uetake(National Hospital Organization), Yi Ba(Tianjin Medical University Cancer Institute and Hospital), Kentaro Yamazaki(Shizuoka Cancer Center), Sae‐Won Han(Seoul National University Hospital), Junichi Sakamoto(Tokai Central Hospital), Taroh Satoh(Osaka University Hospital), Satoru Iwasa(Tokyo National Hospital), Kei Muro(Aichi Cancer Center), Lin Shen(Peking University), Keun‐Wook Lee(Seoul National University Bundang Hospital), Marc Buyse(Institut des Arts de Diffusion), Tomohiro Nishina(Shikoku Cancer Center), Hiroaki Nozawa(The University of Tokyo), Tao Zhang(Fudan University), Wei Wang(Wellcome Sanger Institute), Young Suk Park(Samsung Medical Center), Rui‐Hua Xu(Sun Yat-sen University), Hiroshi Matsumoto, Satoshi Morita(Kyoto University), Sang‐Hee Cho(Chonnam National University), Yanhong Deng(Sun Yat-sen University), Baek‐Yeol Ryoo(Asan Medical Center), Joong Bae Ahn(Yonsei University)
Cited by 15
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k